Research programme: vasopressin receptor modulators - Astellas Pharma

Drug Profile

Research programme: vasopressin receptor modulators - Astellas Pharma

Alternative Names: YM-222546

Latest Information Update: 16 Jul 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Astellas Pharma
  • Class Acetamides; Benzazepines; Small molecules
  • Mechanism of Action Vasopressin 1 receptor antagonists; Vasopressin V2 receptor agonists; Vasopressin V2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Diabetes insipidus; Heart failure; Nocturia

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Diabetes-insipidus in Japan
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Nocturia in Japan
  • 03 Apr 2009 No development reported - Preclinical for Congestive heart failure in Japan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top